Related Experiment Videos
Early and late angiotensin-converting enzyme inhibition in acute myocardial infarction
C Borghi1, S Bacchelli, D Degli Esposti
1Clinica Medica III, University of Bologna, Italy.
Insights
Angiotensin-converting enzyme (ACE) inhibitors help prevent ventricular remodeling after myocardial infarction (MI). Early administration may offer greater remodeling prevention benefits, but optimal timing remains under investigation for diverse patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are known to prevent ventricular remodeling post-myocardial infarction (MI).
- Left ventricular dysfunction following MI is a significant predictor of patient survival.
- The optimal timing for initiating ACE inhibitor therapy after MI is debated.
Purpose of the Study:
- To investigate the optimal timing for ACE inhibitor administration after acute myocardial infarction.
- To determine if early ACE inhibitor administration provides greater benefits in preventing ventricular remodeling compared to late administration.
- To explore how different post-MI patterns influence the effectiveness of ACE inhibitor therapy.
Main Methods:
- Review of existing studies on ACE inhibitor effects in animal and human models post-MI.
- Analysis of factors influencing ventricular remodeling and left ventricular dysfunction.
- Comparison of outcomes based on early versus late initiation of ACE inhibitor treatment.
Main Results:
- ACE inhibitors can attenuate ventricular dilation and remodeling after MI.
- Early ACE inhibitor administration is hypothesized to enhance remodeling prevention.
- The benefit of early administration versus late administration in asymptomatic patients requires further clarification.
- Post-MI patterns, such as anterior versus inferior MI localization, may influence treatment response.
Conclusions:
- ACE inhibitors are beneficial in managing post-MI ventricular dysfunction and remodeling.
- Further research is needed to clarify the optimal timing for ACE inhibitor initiation to maximize patient benefit.
- Individualized treatment strategies considering post-MI patterns may be necessary for effective ACE inhibitor therapy.
Abstract:
Studies in animals and humans have shown that angiotensin-converting enzyme (ACE) inhibitors can prevent or at least attenuate ventricular dilation and remodeling following acute myocardial infarction (MI) and can improve subsequent left ventricular dysfunction, a strong predictor of survival. The question as to which patients will benefit most from ACE inhibitor therapy and the optimal timing of administration of such intervention after the onset of symptoms is still matter of debate, even if it is hypothesized that a greater benefit in terms of remodeling prevention may occur after early administration. However, while it is currently accepted that patients with asymptomatic postinfarctual left ventricular dysfunction can benefit from long-term administration of an ACE inhibitor when therapy is started late, the usefulness of an early administration is still to be clarified. In this setting, the question of early versus late ACE inhibitor treatment has to be related to the different evolving pattern of myocardial infarction with regard to the different degrees of postinfarction ventricular dysfunction and neurohormonal activation, whose extent could influence the effect of ACE inhibition. For example, not all patients with acute MI show progressive ventricular dilation. Early dilation is frequent in patients with anterior localization of necrosis, whereas it is usually not relevant in patients with acute inferior MI. Thus, different postinfarction patterns may differently influence the clinical success of therapeutic interventions, which can be instituted at various stages following acute MI.(ABSTRACT TRUNCATED AT 250 WORDS)